Aortic regurgitation after valve implantation has been shown to be a long -term mortality predictor. The aim of this study was to test the new Direct Flow Medical system, which is more flexible prosthesis with a lower profile that could result in minor aortic regurgitation and less need for post expansion. This multicenter study included<a href="https://solaci.org/en/2015/06/24/salus-new-percutaneous-valve-with-promising-results-regarding-aortic-regurgitation-post-implant/" title="Read more" >...</a>

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve Core with conventional surgery in patients at high surgical risk. Patients with a valve area &lt; 0.8 cm2 , valvular index &le; 0.5 cm2 , a mean gradient of &nbsp;&gt; 40 mmHg or peak speeds above 4m /s<a href="https://solaci.org/en/2015/06/24/corevalve-superior-to-surgical-aortic-valve-replacement-in-high-risk-patients/" title="Read more" >...</a>

So far, there had been no published randomized studies comparing balloon-expandable Edwards&rsquo;s prosthesis and self-expandingCoreValve. The aim of this study was to compare the results between the two thin aortic prosthesis in high-risk surgical patients with severe symptomatic aortic stenosis undergoing valve replacement by percutaneous transfemoral access. This was a multicenter work (five centers in<a href="https://solaci.org/en/2015/06/24/choice-trial-same-mortality-less-aortic-regurgitation-and-need-for-a-second-prosthetic-for-edwards-sapien-xt-valve-versus-medtronic-corevalve/" title="Read more" >...</a>

The sinus node disease is approximately 50 % of pacemaker implants. Atrial fibrillation is a frequent comorbidity of pacemakers and is associated with heart failure, stroke and death. While unnecessary stimulation of the right ventricle has a long term detrimental effect, including an increased risk of atrial fibrillation. In the ventricular pacing mode (MVP, managed<a href="https://solaci.org/en/2015/06/24/minerva-trial-dddr-versus-dddrp-mvp-in-patients-with-bradycardia/" title="Read more" >...</a>

Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia are unknown. We included 253 patients with severe aortic stenosis who received TAVI at 14 sites in Asia (Edwards Sapiens: 140 patients; Medtronic Core Valve: 113 patients). The success rate was<a href="https://solaci.org/en/2015/06/24/clinical-results-of-tavi-in-asia/" title="Read more" >...</a>

The first generation of the Edwards valve was stainless steel and bovine pericardium with a profile of 22 to 24 Fr for transfemoral access and up to 33 Fr to apical access. From 2010 it became cobalt chromium bovine pericardium with a higher profile, (18-19 Fr for transfemoral and 24-26 Fr for transapical). 2,688 patients<a href="https://solaci.org/en/2015/06/24/source-xt-results-of-the-latest-generation-of-the-edwards-valve/" title="Read more" >...</a>

The aim of this study was to evaluate the safety and efficacy of the new device in patients with severe aortic stenosis at high surgical risk. We included 120 patients with a mean age of 84 years and the aortic valve area of 0.7 cm2. The device was successfully implanted in all patients with a<a href="https://solaci.org/en/2015/06/24/reprise-ii-lotus-valve-for-percutaneous-aortic-valve-replacement/" title="Read more" >...</a>

Percutaneous aortic valve implantation ( TAVI ) recently demonstrated its superiority over medical treatment in patients with severe aortic stenosis and high surgical risk. Furthermore patients receiving TAVI showed a survival surgery equivalent to one year. This study included 471 patients with symptomatic severe aortic stenosis discarded of surgery due &nbsp;a very high risk. The<a href="https://solaci.org/en/2015/06/24/corevalve-extreme-risk-promising-results-with-corevalve-in-very-high-risk-patients/" title="Read more" >...</a>